(MENAFN- Newsfile Corp) Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeons, wound-care experts, infectious disease specialists, endocrinologists/diabetologists, cardiovascular and endovascular specialists, nurses, NPs, PAs, residents, fellows, physical therapists, and industry innovators.

"VesCell saves diabetic limbs from amputation, and that saves lives," stated Thomas Smeenk CEO. DFCon remains the world's leading interdisciplinary diabetic foot conference, and we are delighted to be a solution-based participant. Here is why: as compared to a 50% mortality rate within five years for no option patients, the University of Toronto published our treatment generated 0% mortality and limb preservation in 83% of subjects followed for 4.5 years as a midpoint result in our phase II clinical trial! Unblinded the 83% received VesCell. As published, looking at only the patients who presented with wound ulcers before administration of ACP-01, (21 treatment, 8 placebo), Ulcer size in the treated group decreased from a mean of 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months (wounds decreased from the size of a wild strawberry to the size of a grain of sand). There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment. The treatment group had one amputation (4.8%) and one death (4.8%); the placebo group had 2 amputations (25%) and 1 death (12.5%)," and that story needs to be told," Smeenk said.

Across three high-intensity days - Friday, Saturday, and Sunday - Hemostemix will meet with clinicians, researchers, and innovators to highlight the significant outcomes following treatment with ACP-01 (VesCellTM), for vascular and ischemic conditions that underpin chronic wounds and diabetic limb-threatening ischemia.

Financing

The TSXV has approved a non brokered private placement of $518,440, adding 520,090 units ("Units") to the previously announced closing of 4,193,000 units ("Units"), each at a price of $0.11 per Unit. Each Unit consists of one common share in the capital of the Company (a " Common Share ") and one common share purchase warrant (a " Warrant "). Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.15 per share for a period of two (2) years from the closing date of the Offering, subject to the accelerated expiry provision described as follows. If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange (the " Exchange ") is greater than a weighted average price of $0.185 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the date that is 30 days following such press release.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCellTM (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit .

MENAFN02122025004218003983ID1110425918